Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Replimune and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Replimune securities during the Class Period have until September 22, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: FDA Response and Stock Impact - On July 22, 2025, Replimune announced that the FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma treatment [3]. - The CRL indicated that the FDA could not approve the application in its current form, citing inadequacies in the IGNYTE trial and issues related to the confirmatory trial study design [3]. - Following this announcement, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.81 per share on July 22, 2025 [3].

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response regarding the company's lead product candidate RP1 [1][2][5]. Company Overview - Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. Clinical Trial and Regulatory Issues - The company announced positive results from the IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application (BLA) to the FDA based on these results [3][4]. - However, the FDA issued a Complete Response Letter on July 22, 2025, stating that the IGNYTE trial was not considered adequate for demonstrating effectiveness due to the heterogeneity of the patient population [5]. Stock Performance - Following the FDA's announcement, Replimune's stock price fell by more than 75% on July 22, 2025, reflecting investor reaction to the negative regulatory feedback [5].

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Repl ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities between November 22, 2024 and October 21, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the f ...

ATLANTA, July 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming th ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 25, 2025 (GLO ...

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 22, 2024 and July 21, 2025, inclusive (the "Class Perio ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025 in the securities class action first filed by the Firm. ...

SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) publicly traded securities between November 22, 2024 and July 21, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Replimune class action lawsuit. Captioned Jboor v. Replimune Group, Inc., No. 25-cv-012085 (D. Mass.), the Replimune class action lawsuit charges Replimune and certain of Repli ...

Core Viewpoint - Replimune Group, Inc. is under investigation for possible securities fraud following a significant stock decline after the FDA's rejection of its Biologics License Application for RP1 [1][3][4] Group 1: Company Overview - Replimune Group, Inc. is a biotechnology company focused on developing treatments for advanced melanoma [3] - The company received a Complete Response Letter (CRL) from the FDA regarding its application for RP1 in combination with nivolumab [3][4] Group 2: Regulatory Developments - The FDA stated that the IGNYTE trial was not adequate for providing substantial evidence of effectiveness, leading to the rejection of the application [4] - The CRL was issued on July 22, 2025, prior to market open [3] Group 3: Market Reaction - Following the FDA announcement, Replimune's stock fell sharply by $9.52 per share, representing a decline of over 77%, closing at $2.80 on July 22, 2025 [4] Group 4: Legal Actions - The Portnoy Law Firm has initiated an investigation and may file a class action on behalf of investors who lost money due to the stock decline [1][2] - Investors are encouraged to contact the law firm for a complimentary case evaluation regarding their legal rights [2][5]